TY - JOUR
T1 - Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in young children in 2015
T2 - a systematic review and modelling study
AU - for
AU - RSV Global Epidemiology Network
AU - Shi, Ting
AU - McAllister, David A.
AU - O'Brien, Katherine L.
AU - Simoes, Eric A.F.
AU - Madhi, Shabir A.
AU - Gessner, Bradford D.
AU - Polack, Fernando P.
AU - Balsells, Evelyn
AU - Acacio, Sozinho
AU - Aguayo, Claudia
AU - Alassani, Issifou
AU - Ali, Asad
AU - Antonio, Martin
AU - Awasthi, Shally
AU - Awori, Juliet O.
AU - Azziz-Baumgartner, Eduardo
AU - Baggett, Henry C.
AU - Baillie, Vicky L.
AU - Balmaseda, Angel
AU - Barahona, Alfredo
AU - Basnet, Sudha
AU - Bassat, Quique
AU - Basualdo, Wilma
AU - Bigogo, Godfrey
AU - Bont, Louis
AU - Breiman, Robert F.
AU - Brooks, W. Abdullah
AU - Broor, Shobha
AU - Bruce, Nigel
AU - Bruden, Dana
AU - Buchy, Philippe
AU - Campbell, Stuart
AU - Carosone-Link, Phyllis
AU - Chadha, Mandeep
AU - Chipeta, James
AU - Chou, Monidarin
AU - Clara, Wilfrido
AU - Cohen, Cheryl
AU - de Cuellar, Elizabeth
AU - Dang, Duc Anh
AU - Dash-yandag, Budragchaagiin
AU - Deloria-Knoll, Maria
AU - Dherani, Mukesh
AU - Eap, Tekchheng
AU - Ebruke, Bernard E.
AU - Echavarria, Marcela
AU - de Freitas Lázaro Emediato, Carla Cecília
AU - Fasce, Rodrigo A.
AU - Feikin, Daniel R.
AU - Feng, Luzhao
N1 - Publisher Copyright:
© 2017 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license
PY - 2017/9/2
Y1 - 2017/9/2
N2 - Background We have previously estimated that respiratory syncytial virus (RSV) was associated with 22% of all episodes of (severe) acute lower respiratory infection (ALRI) resulting in 55 000 to 199 000 deaths in children younger than 5 years in 2005. In the past 5 years, major research activity on RSV has yielded substantial new data from developing countries. With a considerably expanded dataset from a large international collaboration, we aimed to estimate the global incidence, hospital admission rate, and mortality from RSV-ALRI episodes in young children in 2015. Methods We estimated the incidence and hospital admission rate of RSV-associated ALRI (RSV-ALRI) in children younger than 5 years stratified by age and World Bank income regions from a systematic review of studies published between Jan 1, 1995, and Dec 31, 2016, and unpublished data from 76 high quality population-based studies. We estimated the RSV-ALRI incidence for 132 developing countries using a risk factor-based model and 2015 population estimates. We estimated the in-hospital RSV-ALRI mortality by combining in-hospital case fatality ratios with hospital admission estimates from hospital-based (published and unpublished) studies. We also estimated overall RSV-ALRI mortality by identifying studies reporting monthly data for ALRI mortality in the community and RSV activity. Findings We estimated that globally in 2015, 33·1 million (uncertainty range [UR] 21·6–50·3) episodes of RSV-ALRI, resulted in about 3·2 million (2·7–3·8) hospital admissions, and 59 600 (48 000–74 500) in-hospital deaths in children younger than 5 years. In children younger than 6 months, 1·4 million (UR 1·2–1·7) hospital admissions, and 27 300 (UR 20 700–36 200) in-hospital deaths were due to RSV-ALRI. We also estimated that the overall RSV-ALRI mortality could be as high as 118 200 (UR 94 600–149 400). Incidence and mortality varied substantially from year to year in any given population. Interpretation Globally, RSV is a common cause of childhood ALRI and a major cause of hospital admissions in young children, resulting in a substantial burden on health-care services. About 45% of hospital admissions and in-hospital deaths due to RSV-ALRI occur in children younger than 6 months. An effective maternal RSV vaccine or monoclonal antibody could have a substantial effect on disease burden in this age group. Funding The Bill & Melinda Gates Foundation.
AB - Background We have previously estimated that respiratory syncytial virus (RSV) was associated with 22% of all episodes of (severe) acute lower respiratory infection (ALRI) resulting in 55 000 to 199 000 deaths in children younger than 5 years in 2005. In the past 5 years, major research activity on RSV has yielded substantial new data from developing countries. With a considerably expanded dataset from a large international collaboration, we aimed to estimate the global incidence, hospital admission rate, and mortality from RSV-ALRI episodes in young children in 2015. Methods We estimated the incidence and hospital admission rate of RSV-associated ALRI (RSV-ALRI) in children younger than 5 years stratified by age and World Bank income regions from a systematic review of studies published between Jan 1, 1995, and Dec 31, 2016, and unpublished data from 76 high quality population-based studies. We estimated the RSV-ALRI incidence for 132 developing countries using a risk factor-based model and 2015 population estimates. We estimated the in-hospital RSV-ALRI mortality by combining in-hospital case fatality ratios with hospital admission estimates from hospital-based (published and unpublished) studies. We also estimated overall RSV-ALRI mortality by identifying studies reporting monthly data for ALRI mortality in the community and RSV activity. Findings We estimated that globally in 2015, 33·1 million (uncertainty range [UR] 21·6–50·3) episodes of RSV-ALRI, resulted in about 3·2 million (2·7–3·8) hospital admissions, and 59 600 (48 000–74 500) in-hospital deaths in children younger than 5 years. In children younger than 6 months, 1·4 million (UR 1·2–1·7) hospital admissions, and 27 300 (UR 20 700–36 200) in-hospital deaths were due to RSV-ALRI. We also estimated that the overall RSV-ALRI mortality could be as high as 118 200 (UR 94 600–149 400). Incidence and mortality varied substantially from year to year in any given population. Interpretation Globally, RSV is a common cause of childhood ALRI and a major cause of hospital admissions in young children, resulting in a substantial burden on health-care services. About 45% of hospital admissions and in-hospital deaths due to RSV-ALRI occur in children younger than 6 months. An effective maternal RSV vaccine or monoclonal antibody could have a substantial effect on disease burden in this age group. Funding The Bill & Melinda Gates Foundation.
UR - http://www.scopus.com/inward/record.url?scp=85021970644&partnerID=8YFLogxK
U2 - 10.1016/S0140-6736(17)30938-8
DO - 10.1016/S0140-6736(17)30938-8
M3 - Article
C2 - 28689664
AN - SCOPUS:85021970644
SN - 0140-6736
VL - 390
SP - 946
EP - 958
JO - Lancet
JF - Lancet
IS - 10098
ER -